BioSpace News Archive

Carlsmed announced today that the FDA granted Breakthrough Device designation for its aprevo® technology for treatment of patients with cervical spine disease.

Evaxion Biotech A/S today announced a collaboration with Afrigen Biologics (Afrigen).

Veru Inc. (NASDAQ: VERU) today announced that Mitchell Steiner, M.D., Chairman, President and Chief Executive Officer of Veru, will participate in a fireside chat at the 2023 Cantor Fitzgerald Global Healthcare Conference to be held at the InterContinental New York, Barclay Hotel in New York City on September 28th, 2023 at 10:55 a.m. ET.

Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a company pioneering drug-eluting biomatrix products, today announced that Dr. Randy Mills, President and Chief Executive Officer, will participate on a panel at the Cantor Global Healthcare Conference.

Protara Therapeutics, Inc. today announced that dosing is now underway in its Phase 1b/2 ADVANCED-2 trial evaluating intravesical instillation of TARA-002, the Company’s investigational cell-based therapy.

Silo Pharma, Inc. today announced that based on positive SPC-15 pre-clinical data, it is working with Kymanox as its regulatory partner to assist with the preparation of a pre-Investigational New Drug (IND) package and meeting request with the United States Food and Drug Administration (FDA).

Addex Therapeutics announced that it has led a consortium which has been awarded a €4 million Eurostars grant to support its metabotropic glutamate 2 receptor negative allosteric modulator program for mild neurocognitive disorder.

Merck KGaA, Darmstadt, Germany, a leading science and technology company, announced two new strategic drug discovery collaborations aimed at harnessing powerful artificial intelligence -driven design and discovery capabilities, further advancing the company’s research efforts.

Regulatory News: Sensorion a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat, and prevent within the field of hearing loss disorders, announces its half-year results as of June 30, 2023, alongside its outlook for the remainder of 2023.

Sosei Group Corporation announces the appointment of four new members to its Scientific Advisory Board to advise on the Company’s scientific and early development strategy in support of its corporate objectives.